Macugen U.S. Sales Could Reach Over $200 Mil. In “Choppy” 2006, OSI Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch of Genentech’s pending macular degeneration competitor Lucentis and off-label use of Avastin are factors in Macugen sales projection.
You may also be interested in...
Pfizer/OSI To Curtail Macugen Research In Response To Genentech Competition
Firms will wind down select Phase III trials for Macugen to reallocate resources toward positioning the AMD treatment as a maintenance therapy.
Pfizer/OSI To Curtail Macugen Research In Response To Genentech Competition
Firms will wind down select Phase III trials for Macugen to reallocate resources toward positioning the AMD treatment as a maintenance therapy.
Macugen Labeling Adds Precaution On Angioedema
Pfizer/OSI’s age-related macular degeneration product now advises consideration of a patient’s medical history for hypersensitivity reactions.